SarahWhittleMD

Pediatric Hematology & Oncology • Houston, TX

Physician

Join to view full profile

Dr. Whittle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Whittle's full profile

Already have an account?

Office
6701 Fannin St
Houston, TX 77030
Phone+1 832-824-1000

Education & Training

Baylor College of MedicineMS, Clinical investigation, 2014 - 2016
Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2012 - 2015
Brown UniversityResidency, Pediatrics, 2009 - 2012
Geisel School of Medicine at DartmouthClass of 2009

Certifications & Licensure

TX State Medical License 2015 - 2026
PA State Medical License 2012 - 2012
RI State Medical License 2009 - 2012
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma Start of enrollment: 2014 Apr 01
Active, not recruiting
Phase 1
TAA-Specific CTLS for Solid Tumors (TACTASOM) Start of enrollment: 2015 Apr 01
Completed
Phase 1
High-Risk Neuroblastoma Chemotherapy Without G-CSF Start of enrollment: 2016 Jun 01
Completed
Not Applicable

Publications & Presentations

PubMed

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.
Nathalie Gaspar, Giun-Yi Hung, Sandra J Strauss, Quentin Campbell-Hewson, Filemon S Dela Cruz
JAMA Oncology. 2024-12-01
1 citations
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Anne Miller, Rachel Daum, Tao Wang, Mengfen Wu, Candise Tat
Cytotherapy. 2024-09-01
22 citations
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.
David S Shulman, Sarah B Whittle, Didier Surdez, Kelly M Bailey, Enrique de Álava
NPJ Precision Oncology. 2022-09-17

Press Mentions

Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric CancersNovember 9th, 2021
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric CancersNovember 9th, 2021